Details of the Drug Combination

General Information of Drug Combination (ID: DCRBMF4)

Drug Combination Name
Favipiravir Azithromycin
Indication
Disease Entry Status REF
Infectious Disease Phase 3 [1]
Component Drugs Favipiravir   DMBZ27L Azithromycin   DMS6UOE
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Favipiravir
Disease Entry ICD 11 Status REF
Influenza virus infection 1E30-1E32 Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [3]
Favipiravir Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Mycobacterium RNA polymerase (MycB RNAP) TT79JGK RPOA_MYCTU; RPOB_MYCTU; RPOC_MYCTU; RPOZ_MYCTU Modulator [7]
COVID-19 RNA-directed RNA polymerase (RdRp) TTV1095 R1AB_SARS2 (4393-5324) Inhibitor [8]
------------------------------------------------------------------------------------
Indication(s) of Azithromycin
Disease Entry ICD 11 Status REF
Acute gonococcal cervicitis N.A. Approved [4]
Bronchitis CA20 Approved [5]
Chancroid N.A. Approved [4]
Mycoplasma pneumoniae pneumonia N.A. Approved [4]
Staphylococcus aureus infection N.A. Approved [4]
Streptococcal pneumonia N.A. Approved [4]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [6]
Pneumonia caused by chlamydia N.A. Investigative [4]

References

1 ClinicalTrials.gov (NCT04613271) Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 ClinicalTrials.gov (NCT04336904) Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19
4 Azithromycin FDA Label
5 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 065511.
6 ClinicalTrials.gov (NCT04332107) Azithromycin for COVID-19 Treatment in Outpatients Nationwide. U.S. National Institutes of Health.
7 Favipiravir (T-705), a novel viral RNA polymerase inhibitor.Antiviral Res.2013 Nov;100(2):446-54.
8 Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. Posted April 15, 2020.